Akebia Ther Stock In The News

AKBA Stock  USD 2.26  0.57  33.73%   
Our overall analysis of Akebia Ther's news coverage and content from conventional and social sources shows investors' bearish mood towards Akebia Ther. The specific impact of Akebia Ther news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Akebia Ther's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Akebia Ther headlines in addition to utilizing other, more conventional financial analysis modules. Check out Akebia Ther Backtesting and Akebia Ther Hype Analysis.
For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.

Akebia Ther Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights
https://www.globenewswire.com/news-release/2025/03/06/3038124/37519/en/Akebia-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Discuss-Recent-Business-Highlights.html
 Bullish
Macroaxis News: globenewswire.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.globenewswire.com/news-release/2025/03/04/3036947/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
 Bullish
Macroaxis News: globenewswire.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.globenewswire.com/news-release/2025/02/04/3020785/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
 Bullish
Yahoo News
Akebia Secures $55 Million Term Loan Financing
https://finance.yahoo.com/news/akebia-secures-55-million-term-130000335.html
 Bullish
Yahoo News
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
https://finance.yahoo.com/news/akebia-therapeutics-announces-appointment-nicholas-133000027.html
 Bullish
Yahoo News
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://finance.yahoo.com/news/akebia-therapeutics-reports-inducement-grants-213000492.html
 Bullish
Yahoo News
Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
https://finance.yahoo.com/news/akebia-therapeutics-present-42nd-annual-130000844.html
 Bullish
Yahoo News
Akebia Therapeutics (NASDAQ:AKBA) shareholders have earned a 265% return over the last year
https://finance.yahoo.com/news/akebia-therapeutics-nasdaq-akba-shareholders-133948408.html
 Bullish
Yahoo News
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://finance.yahoo.com/news/akebia-therapeutics-reports-inducement-grants-210500089.html
 Bullish
Yahoo News
Top Penny Stocks for Q4 2023
https://finance.yahoo.com/m/8f9b6d8d-5856-317d-b0fd-836048d51b80/top-penny-stocks-for-q4-2023.html
 Bullish

Akebia Ther Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Akebia and other traded companies coverage with news coverage. We help investors stay connected with Akebia headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Akebia Stock performance. Please note that trading solely based on the Akebia Ther hype is not for everyone as timely availability and quick action are needed to avoid losses.
Akebia Ther's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Akebia Ther investors visualize upcoming and past events in order to time the market based on Akebia Ther noise-free hype analysis.
Akebia Ther stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Akebia earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Akebia Ther that are available to investors today. That information is available publicly through Akebia media outlets and privately through word of mouth or via Akebia internal channels. However, regardless of the origin, that massive amount of Akebia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Akebia Ther news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Akebia Ther relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Akebia Ther's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Akebia Ther alpha.

Akebia Largest EPS Surprises

Earnings surprises can significantly impact Akebia Ther's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-08
2024-06-30-0.05-0.040.0120 
2024-05-09
2024-03-31-0.08-0.09-0.0112 
2025-03-12
2024-12-31-0.075-0.1-0.02533 
2024-11-06
2024-09-30-0.06-0.1-0.0466 
2023-08-25
2023-06-30-0.02-0.06-0.04200 
2024-03-14
2023-12-31-0.040.00320.0432108 
View All Earnings Estimates

Akebia Ther Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Akebia Ther Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
zacks News
13th of March 2025
Akebia Therapeutics Reports Q4 Loss, Tops Revenue Estimates
at zacks.com 
Gurufocus Stories at Macroaxis
4th of March 2025
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
at gurufocus.com 
Google News at Macroaxis
28th of February 2025
Akebia Therapeutics Stock Rating Upgraded by StockNews.com - MarketBeat
at news.google.com 
Google News at Macroaxis
10th of February 2025
Akebia Therapeutics Still Bullish On Vafseo As Auryxias Revenues Decline - Seeking Alpha
at news.google.com 
news
6th of February 2025
Akebia Therapeutics, Inc. CAO Sells 63,424.20 in Stock
at thelincolnianonline.com 
Macroaxis News: globenewswire.com
4th of February 2025
Akebia Therapeutics Reports Inducement Grants UnderNasdaq Listing Rule 5635
at globenewswire.com 
Macroaxis News
3rd of February 2025
Disposition of 55621 shares by Nicholas Grund of Akebia Ther at 2.1 subject to Rule 16b-3
at MacroaxisInsider 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Akebia Ther in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Akebia Ther's short interest history, or implied volatility extrapolated from Akebia Ther options trading.
When determining whether Akebia Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akebia Ther's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akebia Ther Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akebia Ther Stock:
Check out Akebia Ther Backtesting and Akebia Ther Hype Analysis.
For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akebia Ther. If investors know Akebia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akebia Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.22)
Revenue Per Share
0.834
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.09)
Return On Equity
(5.53)
The market value of Akebia Ther is measured differently than its book value, which is the value of Akebia that is recorded on the company's balance sheet. Investors also form their own opinion of Akebia Ther's value that differs from its market value or its book value, called intrinsic value, which is Akebia Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akebia Ther's market value can be influenced by many factors that don't directly affect Akebia Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akebia Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine if Akebia Ther is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akebia Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.